Clinical benefit of enzyme replacement therapy in Fabry disease (Q83144610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Clinical benefit of enzyme replacement therapy in Fabry disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Breunig F

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Weidemann F

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Strotmann J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Knoll A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Wanner C

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

1216-1221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16609685%20AND%20SRC:MED&resulttype=core&format=json

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Patients with Fabry disease on dialysis in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Fabry disease: overall effects of agalsidase alfa treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

An Atypical Variant of Fabry's Disease with Manifestations Confined to the Myocardium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

New insights in cardiac structural changes in patients with Fabry’s disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Cardiac manifestations of Anderson-Fabry disease in heterozygous females

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Enzyme replacement therapy for Fabry disease: proving the clinical benefit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021

Fabry disease: Diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000208

7 January 2021